Physician profile
Stephen Cohen
NPI 1710374111
$6,114.76
in general payments reported to CMS, 2019-2025
42 companies · $438 in 2025
The $438 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $946 · 2021: $1,104 · 2022: $653 · 2023: $903 · 2024: $1,544 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,840 · Education: $45.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,840.12 |
| Education | $45.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $773.61 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $655.60 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $604.56 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $528.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Inspire Medical Systems, INC. | $301.51 | 2023-2024 | Inspire |
| Abbvie INC. | $255.75 | 2019-2025 | Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $247.75 | 2020-2024 | Trintellix |
| Glaxosmithkline, LLC. | $236.41 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.26 | 2020-2023 | Tradjenta, Jardiance |
| Merck Sharp & Dohme LLC | $179.97 | 2020-2024 | Capvaxive, Verquvo, Belsomra |
| Harmony Biosciences LLC | $176.11 | 2024 | |
| Jazz Pharmaceuticals INC. | $171.44 | 2022-2024 | |
| Amgen INC. | $161.56 | 2019-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $139.75 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $133.26 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.